Anti-tumor effect of CDA-II on a human glioma cell
To examine the effect of uroacitide (CDA-II ), an extraction product from normal human urine, on proliferation and differentiation of human glioma SWO-38 cells.
The effects of CDA-II on cellular survival and colony formation were determined by MTT and colony-formation assays. The in vivo anti-tumor effect of CDA-II was examined on transplanted SWO-38 cells in nude mice. In addition, the aterations in cell morphology induced by CDA-II were observed by H&E staining.
Treatment of SWO-38 cells with 1–5 mg/ml of CDA-II for 3 days, resulted in 39.49%± 5.27%~65.05%± 5.89% growth inhibition with an IC50of 2.52 mg/ml. Based on the colony-formation assay, 10 days of CDA-II treatment at a level of 0.3~2.1 mg/ml caused 23.45%± 0.62%~96.22%±1.01% inhibition with an IC50 of 1.03 mg/ml. Furthermore, the inhibitory response was dose-dependent. CDA-II at dosage of 500 mg/kg or 2,000 mg/kg per day for 4 weeks significantly suppressed the growth of human glioma SWO-38 cells in nude mice, with inhibition being 47.77% and 79.94%, respectively (P< 0.05, n=10). H&E staining and light microscopy revealed that CDA-II induced differentiation of the SWO-38 cells.
CDA-II has a significant anti-tumor effect on the human glioma SWO-38 cells, and is a potential and natural anti-glioma therapeutic reagent.
KeywordsCDA-II glioma anti-tumor effect proliferation induced differentiation
Unable to display preview. Download preview PDF.
- 1.Mizunno M, Yoshida J. Tumor necrosis factor-α gene transfer augments anti-fas antibody-mediated apoptosis in human glioma cell. Jpn Cancer Res. 1996, 87:543–547.Google Scholar
- 2.Liao MC. A clever anticancer drug CDA-H. Taipei: ShiMao publisher. 1999; 149–161.Google Scholar
- 3.Zhong XY, Chen YX, Ye SF, et al. Establishment of two cell sublines from SWO-38 glioma cells: an immunohisto-chemical and ultrastructural Study. Int J Modern Cancer Therapy. 2000; 3:34–37.Google Scholar
- 6.Sato etol. Eradicate cancer. Taipei: ShiMao publisher. 1997; 226–231.Google Scholar
- 7.Burynski SR. Antineoplastons: History of the research (1). Drugs Exp Clin Res. 1986; 12:1–9.Google Scholar
- 8.Feng PY, Li Q, Wang ZJ, et al. The clinic study of CDA-H improve life quality of terminal malignancy patient. China Cancer. 2002; 11:108–200.Google Scholar
- 10.Liu JW, Tang Y, Shen Y, et al. Antitumor effect of arsenic trioxide in combination with uroacitides on hepatocellular carcinoma. Chin J Gen Surg. 2003; 18:114–116.Google Scholar
- 11.Liu JW, Tang Y, Shen Y, et al. Apoptosis threshold of hepatoma cell lines induced by As2O3 and CDA-II. Chin J Exp Surg. 2003; 20:116–117.Google Scholar
- 12.Liu JW, Tang Y, Shen Y, et al. Synergistic effect of cell differentiation agent II and arsenic trioxide on induction of cell cycle and apoptosis in hepatotumor cells. World J Gastroentero. 2003; 9:65–68.Google Scholar